GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Thursday, June 4 from 1:00 – 1:25 p.m. EDT.

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005296/en/

Investor Contact:
Shari Annes
Phone: 650-888-0902
Email: [email protected]

Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email: [email protected]

Source: GlycoMimetics, Inc.

You May Also Be Interested In

• AM Best Assigns Issue Credit Ratings to Mercury General Corporation’s New Senior Unsecured Notes
• Ovative Group Wins 2026 AMA Chicago Palmer Award for Engagement
• Entrust Takes on AI-Driven Account Takeover with a New Identity-Centric Approach to Authentication